Abstract : Treatment for chemotherapy-induced nausea and vomiting CINV has improved signi cantly with the development of antiemetic drugs. We conducted a prospective observational study to clarify the quality of life QOL impact of antiemetic therapy recommended by the Japanese Cancer Therapy Association JSCO guidelines for Japanese breast cancer patients receiving an anthracycline plus cyclophosphamide regimen ACR . This was an open, single-center, prospective observational study conducted in Yokohama City University Medical Center. Antiemetic therapy recommended by the JSCO guidelines was implemented for all cases treated therein i.e., aprepitant, dexamethasone, and palonosetron . The primary endpoint was no impact on daily living NIDL rate during a 120-hour period following chemotherapy i.e., overall phase . We use the Japanese version of the Functional Living Index -Emesis FLIE to evaluate the impact of CINV on QOL. There were 118 analyzable cases. The NIDL rate during the overall phase was 44.9 , and was signi cantly lower than the complete response CR rate of 58.5
Introduction
Chemotherapy-induced nausea and vomiting CINV can have major adverse effects on a patient s quality of life QOL 1 2 . The development of novel classes of antiemetic drugs such as aprepitant, neurokinin 1 NK1 receptor antagonists, and palonosetron, a second-generation 5HT 3 receptor antagonist 3 4 , has signi cantly improved the treatment outcomes for CINV, and several guidelines on recommended antiemetic therapy for the prevention of CINV have been published [5] [6] [7] . Guidelines published in 2010 by the Japanese Cancer Therapy Association JSCO 8 led to standardized antiemetic therapy in Japan, and anticancer drugs have been classi ed into four groups based on their risk of inducing emesis, with an optimal antiemetic therapy recommended for each of these groups. For instance, the recommended antiemetic therapy for a highly emetogenic chemotherapy is a combination of aprepitant or fos-aprepitant, dexamethasone, and a 5HT 3 receptor antagonist.
The anthracycline plus cyclophosphamide regimen ACR is used to treat breast cancer patients and is classi ed as a highly emetogenic chemotherapy. In addition, the risk of CINV can be in uenced by various patient-speci c risk factors such as female sex, age 55 years, no alcohol intake, and having a history of morning sickness or motion sickness 10 11 .
Objective indicators such as complete response CR ; i.e., no emetic responses and no use of rescue medication and complete control CC ; i.e., no emetic responses and no nausea are widely used in the symptom assessment of CINV. Then in 2009, the US Food and Drug Administration published the Guidance for industry : patient-reported outcome measures : use in medical product development to support labeling claims 12 , a set of guidelines [5] [6] [7] that recommend the use of patient-reported outcomes PROs . For outpatient chemotherapy, it is also important to consider the subjective patient-reported and daily life outcomes alongside the objective indexes 13 , and many studies have employed the Functional Living Index-Emesis FLIE 14 15 to evaluate the QOL impact of CINV subjectively. Indeed, the Japanese version of the FLIE has shown good reliability and validity 16 , and several survey studies using the FLIE have demonstrated that CINV leads to a notable decrease in QOL 13 17 18 . Nevertheless, there has not yet been a detailed report on the QOL impacts of the antiemetic therapy recommended by the JSCO guidelines a combination of aprepitant, palonosetron, and dexamethasone , with their improved treatment outcomes, for Japanese breast cancer patients receiving a highly emetogenic chemotherapy. Therefore, herein we conducted a prospective observational study to clarify the QOL impact and reported risk factors of the antiemetic therapy recommended by the JSCO guidelines for Japanese breast cancer patients receiving ACR. We also compared the QOL impact by FLIE, with the CR or the CC rates as objective indicators.
Patients and methods

Study design
This was an open, single-center, prospective observational study involving a patient diary and conducted at the Yokohama City University Medical Center. The protocol was approved by 
Antiemetic treatment
The 5HT 3 receptor antagonist called palonosetron has a superior inhibitory effect on CINV in the delayed phase compared to another such drug, granisetron 9 , thus we used palonosetron in this study. During the rst course of chemotherapy, all patients received oral aprepitant 125 mg, intravenous dexamethasone 9.9 mg, and intravenous palonosetron 0.75 mg before chemotherapy on day 1. On days 2 and 3, patients received oral aprepitant 80 mg and oral dexamethasone 8 mg.
On day 4, patients received oral dexamethasone 8 mg. Patients were also prescribed oral prochlorperazine 5 mg as a rescue antiemetic medication, to be used only when nausea and vomiting developed over the 120-hour observation period. We focused solely on the rst course of chemotherapy, and patients were allowed to change their antiemetic therapy from the second course onwards.
Outcome assessment
The acute phase was defined as 0-24 hours following chemotherapy, the delayed phase as 24-120 hours following chemotherapy, and the overall phase as 0-120 hours following chemotherapy. Patients completed a patient diary once per day from days 1 to 5, wherein they recorded emetic episodes, intensity of nausea, and number of times that a rescue antiemetic was needed. Patients also completed the FLIE in order to assess their QOL from days 1 to 5.
Vomiting was de ned as one or more emetic episodes or retching dry heaves , and episodes were considered as separate if they occurred at least 5 min apart. Nausea intensity was evaluated on a 4-point Likert-type scale 0, none ; 1, mild ; 2, moderate ; 3, severe once a day from days 1 to 5, with signi cant nausea de ned by a rating of 2 or more.
We used the Japanese version of the FLIE to assess the impact of CINV on QOL 16 . The FLIE is a modi ed version of the Functional Living Index -Cancer, which is a representative measure of QOL for cancer patients with established reliability and validity 14 . The FLIE contains 18 items assessing the effect of CINV on patients daily lives, and contains separate domains for the impacts of nausea and vomiting. The rst item in each domain asks the patient to rate how much nausea vomiting they have experienced, and then the remaining eight items assess the impact of nausea vomiting on the following aspects of a patient s daily life : ability to enjoy meals / liquids, ability to prepare meals / do household tasks, ability to perform daily functions, ability to perform usual recreation, ability to enjoy leisure activities, willingness to spend time with family and friends, extent to which the side effect has caused personal hardship and / or hardship on others.
For each item, participants rate the impact of both nausea and vomiting on daily life, thus producing two scores for each item, and all items are rated on a visual analogue scale VAS ranging from 1 not at all to 7 a great deal . The total score ranged from 18 to 126, and we de ned a total score of less than 36 as indicating no impact on daily living NIDL . For each domain, scores ranged from 9 to 63, and we de ned a total score of less than 18 as indicating NIDL of nausea or vomiting.
The CR rate was de ned as the proportion of patients with no emetic episode and no use of rescue antiemetic medication. Furthermore, the complete control CC rate was de ned as the proportion of patients with no emetic episode, no use of rescue medication, and no nausea.
The primary endpoint in this study was NIDL rate during the overall study phase. Other endpoints included differences in NIDL, CR, and CC rates in the acute, delayed, and overall phases. We also investigated the in uence of certain risk factors on NIDL rate including age 55 years, no alcohol intake, history of motion sickness, and history of morning sickness in the acute, delayed, and overall phases.
Statistical analysis
A 2 test was used to compare NIDL rate with the CR or CC rate in each phase. To assess the in uence of the risk factors on NIDL rate, we conducted a multivariate logistic regression analysis with NIDL as the outcome variable and each risk factor as an explanatory variable. We specifically examined whether the risk factors were associated with not achieving NIDL. We also examined the relationship between number of risk factors and NIDL rate using the Cochran-Armitage trend test. Analyses were carried out with SPSS Statistics 24.0, and JMP Pro 12 was used to conduct the Cochran-Armitage trend test. All reported P-values were two-sided, and only P-values 0.05 were considered statistically signi cant.
Results
Patient characteristics
From June 2014 to December 2016, we enrolled 121 patients were enrolled in the study, and 118 of these were included in the analysis. Three patients were excluded because they either failed to complete the patient diary n 2 or changed hospitals n 1 . Table 1 lists the characteristics of the analyzed patients. All patients were women, and the median age of patients was 54 years range 27-76 . Across the treatment regimens, 71 patients were on FEC, 44 patients on EC, and 3 patients on AC. The aim of treatments included perioperative adjuvant chemotherapy 89.0 , n 105 and Suppression of advance or recurrence 11.0 , n 13 . 
Antiemetic outcomes
The antiemetic outcomes are shown in Table 2 . The acute phase had the highest rates of vomiting and signi cant nausea, and they tended to decrease with time. Figure 1 details the FLIE-based QOL assessment results. During the overall phase, the prevalence of patients with NIDL was 53 44.9 , and in all phases, the NIDL of nausea tended to be lower than that of vomiting. Figure 2 shows the comparison between the NIDL rate and the CR or CC rate. The NIDL rate was signi cantly lower than the CR rate in all phases, but was signi cantly higher than the CC rate in all phases. Table 3 shows the univariate comparisons of NIDL rate by the presence or absence of risk factors for the different phases. The results indicated that age 55 years and history of morning sickness were signi cantly associated with a low NIDL rate in the acute, delayed, and overall phases. The multivariate logistic regression analyses are also detailed in Table 3 . Again, age 55 years and a history of morning sickness were extracted as independent risk factors of a failure to achieve NIDL P 0.05 . Table 4 shows the relationship between the number of reported risk factors and NIDL rate in each phase. The NIDL rate tended to decrease signi cantly as the number of reported risk factors increased in all three phases P 0.05 .
Impact on QOL
Risk factors
Discussion
This was a single-center, prospective, observational study on the QOL impact of aprepitant, dexamethasone, and palonosetron combination therapy for ACR in Japanese breast cancer patients. Notably, the NIDL rates in this study remained at 44.9 in the overall phase Figure 1 .
In Japan, the most recommended antiemetic therapy for a highly emetogenic chemotherapy is the combination of NK-1 receptor antagonist, dexamethasone, and 5HT 3 receptor antagonist preferred one is palonosetron 19 . The CR rate in the overall phase of a randomized doubleblind comparative study on the effectiveness of this particular therapy among 326 breast cancer patients undergoing ACR in Japan was 54.9 20 , which is similar to the CR rate of this study.
In contrast, another randomized double-blind comparative study 9 on the effectiveness of this combination therapy for patients receiving Japanese cisplatin treatment reported a CR rate of 65.7 , which is substantially higher than that of the previous study 20 targeting ACR and the present study. In addition, in an integrated analysis of randomized controlled trials 21 , the incidence of CINV with ACR was higher than that for patients receiving a cisplatin regimen. Therefore, while both cisplatin and ACR are highly emetogenic chemotherapies, the latter seems to need more attention for CINV management when it is used to treat breast cancer. Several survey studies that investigated QOL using the FLIE questionnaire targeted highly or moderately emetogenic chemotherapy involving a combination of corticosteroid and 5HT 3 receptor of the patients and due to nausea in 76.6 of the patients. For the rst time in this study, we targeted Japanese patients with breast cancer receiving an ACR regimen of aprepitant, dexamethasone, and palonosetron, and investigated QOL using FLIE questionnaires. And we found that NIDL for nausea was 36. 4 and NIDL for vomiting was 78.8 in the overall phase. Therefore, we found no signi cant improvement in QOL compared to previous studies.
We also found that the incidence of signi cant nausea during the overall phase was higher than the incidence of vomiting 30.5 vs. 24.6 , and that NIDL could not be achieved for nausea 36.4 , but could generally be achieved for vomiting 78.8 . Together, these results indicate that the in uence of nausea on QOL was considerable. Furthermore, the NIDL rate, which is an index of QOL, was signi cantly lower than the CR rate, possibly because nausea was not included as an evaluation indicator when measuring CR rate. A previous study investigating the effect of CINV on QOL similarly presumed that nausea has a greater negative impact on QOL than does vomiting because vomiting is a short-term event, whereas nausea is a prolonged feeling 13 ; however, since the NIDL rate in this study was signi cantly higher than the CC rate no emetic responses and no nausea , we might infer that the CC rate is not the most ideal goal of antiemetic therapy and that mild nausea probably did not lead to a lower QOL. By contrast, signi cant nausea might have a large in uence on QOL, and our results indeed suggest that the CR rate is insuf cient for evaluating the QOL effects of antiemetic therapy. Consequently and with the growing use of outpatient chemotherapy, proper assessment of QOL using subjective indexes, including nausea, is essential for CINV management, and it might be necessary to calculate NIDL rates using the FLIE to effectively evaluate the impact of CINV on patient QOL. One previous study investigating CINV and QOL among breast cancer patients undergoing ACR conducted in Canada, which also used the FLIE, reported a CR rate of 51 and an NIDL rate of 63.5 22 ; also, in contradiction to the present study results, the NIDL rate was higher than the CR rate. A previous study in Japan using the FLIE Japanese version attributed this difference in rates to the period used to de ne NIDL 23 ; in the Canadian study, the FLIE was obtained 120 hours following treatment, and participants were asked to rate the last 5 days, whereas in the FLIE Japanese version, the questionnaire was administered to patients every 24 hours. In addition, the FLIE is a subjective evaluation of QOL and thus possibly affected by memory, which is likely to become increasingly ambiguous over time. Thus, the FLIE Japanese version used in our study might more accurately measure QOL 23 .
For Japanese patients receiving ACR for breast cancer, the NIDL rate remained at about 50 , despite the use of effective antiemetics. This might be because a large number of the cases had risk factors of CINV, such as being young and female, and in this study, the NIDL rate of individuals aged 55 years or with a history of morning sickness was signi cantly lower Table 3 . In addition, the NIDL rate tended to decrease as the number of known risk factors increased in this study Table 4 . On the other hand, the NIDL rate was over 90 for cases without any risk factors. Thus, the antiemetic therapy seemed adequate only when no risk factors were present. Therefore, individualized antiemetic therapy taking risk factors into account should be considered. Recently, the usefulness 24 of combined antiemetic treatment of olanzapine with aprepitant, dexamethasone, and a 5HT 3 receptor antagonist has been demonstrated. Thus, patients with many risk factors might improve their QOL by adding olanzapine in conjunction with other antiemetics. Since this study is a single-arm, single-center observational study, we cannot deny the possibility of omitting other confounders affecting QOL, or the possibility of in uencing factors within the treatment environment. Thus, a more detailed and larger-scale study is warranted.
In summary, among Japanese patients with breast cancer receiving ACR, even usiug the recommended combination therapy of aprepitant, dexamethasone, and palonosetron, the NIDL rate was only about 45 . It is therefore necessary to develop a more effective antiemetic therapy that takes patient-level risk factors into account to improve overall patient QOL. In addition, the NIDL rate was signi cantly lower than the CR rate in this study, suggesting that the CR rate is insuf cient for evaluating the effect of antiemetic therapy on a patient s QOL.
